Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Puerta de Hierro (9)

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

  2. Hyperprogression as a distinct outcome after immunotherapy

    Cancer Treatment Reviews, Vol. 70, pp. 16-21

2017

  1. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

    BMC Cancer, Vol. 17, Núm. 1

2015

  1. BRCA1 Alternative splicing landscape in breast tissue samples

    BMC Cancer, Vol. 15, Núm. 1

  2. Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease

    Translational Research, Vol. 166, Núm. 6, pp. 783-787

2009

  1. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2007

  1. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 6, Núm. 7, pp. 522-528

2004

  1. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer

    Oncology Reports, Vol. 12, Núm. 3, pp. 621-629

2002

  1. Stromelysin-1 promoter mutations impair gelatinase B activation in high microsatellite instability sporadic colorectal tumors

    Cancer Research, Vol. 62, Núm. 13, pp. 3855-3860